The FDA is concerned that Eli Lilly’s newly approved obesity pill Foundayo might come with a risk for major cardiovascular events and liver damage, and

Replimune’s second complete response letter for its cancer therapy last week is already leading to multiple rounds of layoffs and existential questions about the company’s

Another stock offering blitz is adding more fuel to biotech investors’ belief in the sector. Revolution Medicines anchored Monday’s offering surge, while Spyre Therapeutics and

This year is pivotal for biopharma, and we need your perspective on where things are going. Endpoints is fielding the next Biopharma Sentiment Index (BPSI)

Johnson & Johnson executives believe the worst of the biosimilar pressure facing Stelara is behind them, and feel confident enough to predict significant growth through